Test your knowledge below on pooled data from ADvocate1 and ADvocate2 trials and stay up to date with the latest clinical advancements in atopic dermatitis treatment.
Atopic dermatitis affects approximately 10 to 20% of children and up to 10% of adults worldwide, with many experiencing moderate-to-severe disease with a significant impact on quality of life. Despite its prevalence, effective treatment options have historically been limited, particularly for patients who do not respond to topical corticosteroids or conventional systemic therapies. Until recently, therapeutic advancements have been slow, leaving many patients with persistent symptoms and few alternatives.
However, in 2024 alone, 4 therapies—lebrikizumab (Ebglyss), roflumilast cream (Zoryve), nemolizumab (Nemluvio), and tapinarof cream 1% (Vtama)—received approvals for atopic dermatitis in different populations, marking a significant expansion of available treatment options.
On September 13, 2024, the US Food and Drug Administration approved lebrikizumab for the treatment of adults and children aged 12 years or older with moderate-to-severe atopic dermatitis that has not been adequately controlled using topicals. This approval was based on ADvocate 1, ADvocate 2, and ADhere clinical studies. ADvocate 1 and 2 were 52-week, phase 3 global studies assessing lebrikizumab as monotherapy, and the ADhere study tested the drug in combination with topical corticosteroids over the course of a 16-week period.
This quiz is 2 of 4 in a series designed to reinforce knowledge of the data supporting these new treatments. By engaging with these quizzes, clinicians can better understand how these therapies fit into clinical practice and improve patient outcomes.
Interested in dermatology? Learn more about the annual Revolutionizing Atopic Dermatitis (RAD) Conference, hosted by HCPLive, Dermatology Times, and our CE/CME partner Physicians’ Education Resource.
Test your knowledge below on pooled data from ADvocate1 and ADvocate2 trials and stay up to date with the latest clinical advancements in atopic dermatitis treatment.
1. True or False: Lebrikizumab is a dual interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor, directly blocking both cytokines.
References: